Mateon Therapeutics, Inc. (OTCMKTS:MATN – Get Free Report) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.07 and traded as high as $0.0988. Mateon Therapeutics shares last traded at $0.0971, with a volume of 121,836 shares trading hands.
Mateon Therapeutics Price Performance
The firm’s 50 day moving average is $0.09 and its 200 day moving average is $0.07. The firm has a market cap of $8.76 million, a P/E ratio of -4.86 and a beta of 1.33.
Mateon Therapeutics Company Profile
Mateon Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.
Recommended Stories
- Five stocks we like better than Mateon Therapeutics
- What is an Earnings Surprise?
- Wall Street’s Sleeping Giant: Is Amazon About to Wake Up?
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Checkmate in the Cloud: ServiceNow’s Shopping Spree
- Find and Profitably Trade Stocks at 52-Week Lows
- The Contrarian Case for MSTR Amid MSCI Delisting Debacle
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
